Finanzen von Structure Therapeutics Inc (GPCR)GPCRStructure Therapeutics Inc

Evaluating the bottom line, Structure Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -20.21%, provide a clear picture of how effectively GPCR converts its operational activities into shareholder value.

In the context of the broader market, GPCR competes directly with industry leaders such as BHVN and BRVE. With a market capitalization of $1.96B, it holds a leading position in the sector. When comparing efficiency, GPCR's gross margin of N/A stands against BHVN's N/A and BRVE's N/A. Such benchmarking helps identify whether Structure Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

The company has reported negative net income for several quarters, with the latest figures showing a net loss of $106,159,000 for Q2 2026. The forward P/E ratio is not applicable as the company is currently not profitable, and the price-to-book ratio is 1.35, indicating it is trading slightly above its book value.